Bowles EJ, Wellman R, Feigelson HS et al.; Pharmacovigilance Study Team.
Group Health Research Institute, Seattle, WA, USA.
J Natl Cancer Inst 2012;104:1293–305.
Lukas Schwentner’s review: In this study, the authors investigated the impact of anthracycline and trastuzumab on the rates of heart failure and cardiomyopathy in a retrospective, population-based cohort study. Several clinical trials have demonstrated that women with breast cancer treated with anthracycline or trastuzumab are at an increased risk of heart failure and/or cardiomyopathy, but the generalizability of these findings is unknown. The study included 12500 women with invasive breast cancer. The authors used administrative procedure and pharmacy codes to identify anthracycline, trastuzumab, and chemotherapy application. They classified heart failure and cardiomyopathy based on the International Classification of Diseases-9; because of the retrospective design it was not possible to analyze left ventricular ejection fraction (LVEF) using echocardiography.